SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 20-F/A - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]: [Amend]
SEC Accession No. 0001213900-24-026622
Filing Date
2024-03-27
Accepted
2024-03-27 16:34:36
Documents
18
Period of Report
2023-10-31

Document Format Files

Seq Description Document Type Size
1 AMENDMENT NO. 2 TO FORM 20-F ea0202617-20fa2_clear.htm   iXBRL 20-F/A 61995
2 CERTIFICATION ea020261701a2ex12-1_clear.htm EX-12.1 10350
3 CERTIFICATION ea020261701a2ex12-2_clear.htm EX-12.2 10365
4 CERTIFICATION ea020261701a2ex13-1_clear.htm EX-13.1 3706
5 CERTIFICATION ea020261701a2ex13-2_clear.htm EX-13.2 3763
  Complete submission text file 0001213900-24-026622.txt   337286

Data Files

Seq Description Document Type Size
6 XBRL SCHEMA FILE cmnd-20231031.xsd EX-101.SCH 3267
7 XBRL DEFINITION FILE cmnd-20231031_def.xml EX-101.DEF 19223
8 XBRL LABEL FILE cmnd-20231031_lab.xml EX-101.LAB 38649
9 XBRL PRESENTATION FILE cmnd-20231031_pre.xml EX-101.PRE 20062
22 EXTRACTED XBRL INSTANCE DOCUMENT ea0202617-20fa2_clear_htm.xml XML 7313
Mailing Address 101-1220 WEST 6TH AVENUE VANCOUVER, BRITISH COLUMBIA Z4 V6H1A5
Business Address 101-1220 WEST 6TH AVENUE VANCOUVER, BRITISH COLUMBIA Z4 V6H1A5 972-54-5704749
Clearmind Medicine Inc. (Filer) CIK: 0001892500 (see all company filings)

IRS No.: 000000000 | State of Incorp.: Z4 | Fiscal Year End: 1031
Type: 20-F/A | Act: 34 | File No.: 001-41557 | Film No.: 24791348
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)